治疗慢性乙型肝炎的新药拉咪呋啶和法昔洛韦  

NEW DRUGS FOR CHRONIC HEPATITIS B, LAMIVUDINE AND FAMCICLOVIR

作　　者：王慧芬[1] 张战红[1] 

机构地区：[1]解放军第302医院

出　　处：《中国新药杂志》1999年第4期222-224,共3页Chinese Journal of New Drugs

摘　　要：新药拉咪呋啶和法昔洛韦是治疗慢性乙型肝炎的新型核苷类似物。口服拉咪呋啶或法昔洛韦可使大多数患者血清转氨酶恢复正常及组织学病变明显改善，还可迅速降低血清ＨＢＶＤＮＡ水平及阻止肝炎、肝移植患者肝炎复发。The efficacy and safety of new nucleotide analogues lamivudine and famciclovir were studied in the patients with chronic hepatitis B and the patients receiving liver transplant. The results showed that the two drugs could rapidly decrease HBV DNA levels in the serum from the patients with chronic hepatitis B and prevent the recurrence of hepatitis B in some of the liver transplanted patients. Normalization of aminotransferases and histological improvement in most of patients could also be demonstrated. However, when there was genetic mutation of the virus in the bodies of the patients or the drug treatment was stopped, the hepatitis would recur in some of the patients.

关 键 词：慢性 乙型肝炎 核苷类似物 治疗 拉咪呋啶 

分 类 号：R512.620.5[医药卫生—内科学]